Form 10-Q Summary
Filing identity: The provided filing is for Zeta Acquisition Corp. II, not Whitehawk Therapeutics, Inc. It covers the quarter ended June 30, 2011 and was filed August 15, 2011. The company identified itself as a development-stage, blank-check and shell company.
Business Context and Reporting Period
Zeta Acquisition Corp. II was formed in November 2007 to identify and complete a business combination with an operating company. It had no operating business, generated no revenue since inception, and had not identified or held discussions with a potential target. The company reported 5,000,000 common shares outstanding as of August 9, 2011.
Financial Condition and Results
| Metric | Three Months Ended June 30, 2011 | Six Months Ended June 30, 2011 | Comparable Period |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Net loss | $(6,760) | $(11,914) | $(5,576) and $(9,882), respectively, in 2010 |
| Operating loss | $(5,862) | $(10,129) | $(5,121) and $(9,057), respectively, in 2010 |
| Net loss per share | $(0.00) | $(0.00) | $(0.00) in each 2010 period |
| Operating cash flow | Not separately reported | $(17,668) | $(15,382) in 2010 |
- General and administrative expense was $5,862 for the quarter and $10,129 for the six months, compared with $5,121 and $9,057 in the 2010 periods.
- Interest expense was $898 for the quarter and $1,785 for the six months, compared with $455 and $825 in 2010.
- Cash and cash equivalents declined to $9,230 at June 30, 2011 from $26,898 at December 31, 2010.
- Total assets were $15,480, including $6,250 of prepaid expenses. Current liabilities were $68,385, including $60,000 of notes payable to stockholders, $6,185 of accrued expenses and $2,200 of accounts payable.
- Stockholders’ deficit increased to $(52,905) from $(40,991) at December 31, 2010. Accumulated deficit since inception was $102,905.
- No investing cash flows occurred. There was no financing cash flow during the first six months of 2011; financing provided $10,000 in the comparable 2010 period.
- The notes payable to stockholders bear 6% interest, are unsecured and due on demand. Interest accrued and unpaid at June 30, 2011 was $4,510.
Material Changes and Outlook
- Six-month net loss increased approximately 21% from $9,882 in 2010 to $11,914 in 2011, while operating cash use increased from $15,382 to $17,668.
- Liquidity weakened materially as cash declined by $17,668 during the first six months and current liabilities exceeded current assets by $52,905 at June 30, 2011.
- Management planned to continue searching for a suitable acquisition candidate and expected costs for SEC reporting and acquisition investigations.
- Management expected to fund operations through existing cash, deferred service-provider fees, stockholder or management loans, or equity financing connected with a future reverse merger. The filing provides no assurance that additional funding will be available.
Risks, Contingencies, and Unusual Items
- The financial statements were prepared on a going-concern basis, but management stated that continued operations depended on future financing, profitable operations, and completing a suitable business combination.
- The company had no revenues or cash-generating operations and was dependent on related parties for continued funding.
- Any future target could be financially unstable, early-stage, or operating in a high-risk industry. Management expected it might complete only one business combination, creating concentration and diversification risk.
- Deferred tax assets of approximately $15,800 were fully offset by a valuation allowance because realization was uncertain.
- The company used office space and equipment provided by an officer and director at no cost on a month-to-month basis; management considered the value immaterial.
- No material legal proceedings, unregistered equity sales, senior-security defaults, or material off-balance-sheet arrangements were reported.
- Management concluded that disclosure controls and procedures were effective as of June 30, 2011, with no material changes in internal control during the quarter.
Investor Verification Items
- Verify the issuer name and filing accession because the supplied metadata identifies Whitehawk Therapeutics, while the filing identifies Zeta Acquisition Corp. II.
- Confirm whether the $60,000 of stockholder notes remained payable on demand and whether additional related-party funding was obtained after June 30, 2011.
- Assess the company’s ability to fund SEC reporting and acquisition efforts with only $9,230 of cash and no revenue.
- Review subsequent filings for any business combination, reverse merger, financing, change in control, or change of corporate name.
- Evaluate the going-concern risk and the absence of an identified acquisition target or committed source of financing.